Core Insights - The company, BaiAoSaiTu, is an innovative biotechnology firm focused on drug development, aiming to become a global source of new drugs through proprietary gene editing technologies [1] Group 1: Business Model and Growth - BaiAoSaiTu has developed the RenMice platform, which includes various therapeutic monoclonal antibodies and other advanced antibody formats, indicating a high growth potential and significant technological barriers [1] - The company has achieved rapid growth in its preclinical products and services, with a significant increase in animal model sales from 50 million yuan in 2019 to 389 million yuan projected for 2024, and 274 million yuan in the first half of 2025, reflecting a year-on-year growth of 56.1% [2] Group 2: Competitive Landscape and Strategy - The global competition in early drug research is intense, and the "Thousand Mice, Ten Thousand Antibodies" model enhances development efficiency by allowing parallel comparisons of multiple targets, which helps pharmaceutical companies improve research efficiency and clinical success rates [3] - The antibody business started in 2020 with revenues of 41 million yuan, which is expected to reach 163 million yuan in the first half of 2025, showing a year-on-year growth of 37.8% [3] Group 3: Financial Projections - Revenue forecasts for the company are projected at 1.387 billion yuan, 1.809 billion yuan, and 2.306 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 41.5%, 30.4%, and 27.4% [3] - The net profit attributable to the parent company is expected to be 147 million yuan, 335 million yuan, and 527 million yuan for the same years, with significant growth rates of 339.3%, 127.3%, and 57.4% respectively [3]

Core Viewpoint - The article highlights the rapid growth and transformation of Baiaosaitu, a biotechnology company, which has evolved from a gene-targeting service provider to a product-driven entity in the innovative drug development sector, emphasizing its commitment to technological innovation and human health [2][3]. Company Development - Baiaosaitu has undergone two major transformations since its inception, moving from a gene-targeting service provider to a biotechnology company focused on product development [2]. - The company was founded in 2008 by Shen Yulei, who was inspired by his academic background in immunology and gene editing technology [3]. - In 2015, the company shifted its strategy from CRO to a "CRO + product" model, focusing on the sale of model animals and the development of a comprehensive human antibody platform [3][4]. Financial Performance - In 2024, Baiaosaitu achieved a revenue of 980 million yuan, representing a year-on-year growth of 36.76%, and a net profit of 33.54 million yuan, marking a successful turnaround [6]. - Currently, 70% to 80% of the company's revenue comes from product sales, contrasting sharply with traditional CRO companies where service revenue dominates [5]. Business Strategy - The company has developed a dual business model with two core business lines: the humanized mouse model business and the human antibody business, which are expected to drive growth synergistically [6][7]. - The humanized mouse model business has maintained an annual growth rate of 30% to 40%, while the human antibody business is entering a rapid growth phase due to the maturity of the "Thousand Mice, Ten Thousand Antibodies" platform [7]. Global Expansion - Baiaosaitu has established a significant global presence, with approximately 70% of its revenue coming from overseas markets and partnerships with major pharmaceutical companies [8]. - The company aims to become a "global source of new drugs," focusing on enhancing its brand and expanding its antibody library to support drug development [9]. Future Outlook - The listing on the Sci-Tech Innovation Board is seen as a crucial step in Baiaosaitu's global strategy, with plans to continue investing in innovative animal models and expanding its antibody library [9].

Core Points - The article highlights the selection of Liang Wenfeng and Du Mengran as two of the top ten scientists of 2025 by the journal Nature, showcasing significant contributions in their respective fields [2][3] - Liang Wenfeng is recognized as a "technology disruptor" for developing the DeepSeek large language model, which has made a substantial impact on the scientific community [2] - Du Mengran is acknowledged for her groundbreaking discovery of the deepest animal ecosystem on Earth, located below 9,000 meters in the ocean, marking a significant achievement in marine science [2] Summary by Categories - **Recognition of Scientists** - Liang Wenfeng and Du Mengran are included in Nature's list of top ten scientists for 2025, emphasizing their innovative work in artificial intelligence and deep-sea research respectively [2][3] - **Liang Wenfeng's Contributions** - The DeepSeek large language model developed by Liang's company has been described as a "great boon" for scientists, indicating its potential to revolutionize research methodologies [2] - **Du Mengran's Discoveries** - Du's research has led to the identification of a previously unknown deep-sea ecosystem, providing unprecedented insights into marine biology and ecology [2]

股票简称：百奥赛图 股票代码：688796 百奥赛图（北京）医药科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. （北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街12号院） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） 北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层 二〇二五年十二月九日 特别提示 百奥赛图（北京）医药科技股份有限公司（以下简称"百奥赛图"、"本公司"、 "发行人"或"公司"）股票将于 2025 年 12 月 10 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上市 初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 2 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、准确、 完整，承诺上市公告书不存在虚假记载、误导性陈述或者重大遗漏，并依法承担法律责 任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不表明对 本公司的任何保证。 本 公 司 提 醒 广 大 投 ...

Core Viewpoint - The research conducted by the Shenzhen Agricultural Genomics Institute of the Chinese Academy of Agricultural Sciences reveals the unique genetic adaptations of wild boar populations during their migration across the Eurasian continent over millions of years, providing new insights into how large mammals respond to environmental changes [2][4]. Group 1: Migration and Evolution - The study reconstructs the evolutionary and migratory history of wild boars, indicating that Asian wild boars diverged from their Southeast Asian relatives approximately 3.6 million years ago, with some populations migrating north into southern China [4]. - By 1.8 million years ago, another group of wild boars continued westward into Central Asia, where they diversified into new branches around 900,000 years ago, eventually leading to the ancestors of modern European wild boars [4][5]. Group 2: Genetic Adaptations - The research identified several key genes in the genomes of Central Asian wild boars that underwent strong natural selection, particularly those related to fat metabolism, thermoregulation, and skin pigmentation [4][5]. - Specific genetic variations in the LPIN1 gene enhance fat storage, allowing wild boars to survive food shortages during harsh winters, while changes in the ALPK2 gene may increase muscle mass, contributing to their robust physique [5]. Group 3: Research Methodology and Implications - The study employed a multi-layered and comprehensive research approach, integrating genomic, transcriptomic, and epigenetic data to validate key genetic variations, significantly enhancing the reliability of the findings [5][6]. - The findings clarify the migratory patterns of wild boars and provide valuable genetic resources for breeding new pig varieties, as well as evolutionary biological insights to address future challenges such as climate change and disease outbreaks [6].

Core Points - The EU has reached an agreement on new regulations that pave the way for the use of gene editing technology in agriculture, aimed at helping farmers cultivate healthier plant and animal varieties to address climate change challenges [1][3] - The new regulations exempt gene-edited organisms from the EU's GMO regulatory framework, distinguishing gene editing from traditional genetic modification by simulating natural breeding processes without introducing cross-species DNA [1][3] Industry Impact - The agricultural protection industry views this technology as essential for enhancing crop and livestock resilience against extreme weather, pests, and diseases, providing EU farmers a competitive edge against countries like the US that already permit gene editing [3][4] - The EU Council stated that the new regulations will make the EU food system safer and more sustainable, enabling the cultivation of crops that are more resilient to climate change and pests, with higher yields and reduced reliance on fertilizers and pesticides [3][4] Regulatory Changes - The new measures are expected to reduce administrative burdens while enhancing the competitiveness of breeding companies and farmers [4] - The regulations still require formal approval from the European Parliament and the EU Council before coming into effect [3] Stakeholder Reactions - The EU agricultural association Copa-Cogeca welcomed the agreement as a historic advancement and the only practical solution for farmers under the EU's Green Deal framework [5] - Environmental organization "Friends of the Earth" criticized the regulatory relaxation, labeling it as a deregulation of new genetically modified organisms and a "pass" for the biotechnology industry [6]

Core Viewpoint - Nanmo Biology focuses on the research, production, sales, and related technical services of genetically modified animal models, primarily using mice, rats, and nematodes as model organisms [1] Company Overview - The company utilizes gene editing technology to insert, delete, or modify endogenous genes, creating biological models that simulate specific physiological, pathological, and cellular characteristics of humans [1] - The genetically modified animal models produced by the company mainly refer to genetically modified mouse models [1] Strategic Positioning - The company does not engage in any technical collaboration or strategic partnership with Yizhiming [1]

Group 1: New Stock Offerings - Two new stocks are available for subscription in the upcoming week, with one on November 24 and another on November 28 [1] - The first company, Moer Technology (688795), is one of the few domestic companies with full GPU development capabilities, with a total market value of 457.2 billion [1] - Moer Technology's issuance price-to-earnings ratio is 27.06, significantly lower than the industry average of 60.1 [1] - The second company, BioAstute (688796), is a preclinical CRO and biotechnology firm, with an industry average price-to-earnings ratio of 39.7 [2] Group 2: Company Highlights - Moer Technology's MTT S80 graphics card has single-precision floating-point performance close to NVIDIA's RTX 3060, and its MTT S5000-based intelligent computing cluster exceeds the efficiency of comparable foreign GPU clusters [1] - BioAstute specializes in preclinical pharmaceutical research services, offering innovative model animals through its self-developed gene editing technology [2]

Core Insights - The article highlights the growing importance of biomanufacturing in China's economic strategy, positioning it alongside quantum technology and embodied intelligence as a key future industry [1] - The shift from a generics-based pharmaceutical industry to one focused on innovative drug development has garnered significant global attention [1] Industry Overview - Biomanufacturing is recognized for its potential to revolutionize various sectors, including healthcare and agriculture, with examples such as rice-derived human serum albumin and gene editing technologies [2] - The application of biomanufacturing extends to environmental solutions, such as biodegradable plastics and the production of hyaluronic acid using microorganisms [2] Health and Longevity - China's average life expectancy is projected to reach 79 years by 2024, reflecting advancements in healthcare, though challenges remain in managing diseases like Alzheimer's [3] - A shift in medical focus from treatment to prevention and health maintenance is emphasized, with early disease detection being crucial for improving life quality and reducing healthcare costs [4][5] Global Positioning - China is recognized as a leading player in the biotechnological field, competing closely with the US, and is noted for its cost-effective innovations in drug development [6][7] - The disparity in drug pricing between China and the US is highlighted, with Chinese drugs being significantly more affordable, enhancing accessibility [6] Future Prospects - The article discusses the potential for China's biomanufacturing sector to expand internationally, emphasizing the importance of addressing global health needs rather than solely focusing on high-profit markets [8] - The upcoming implementation of new regulations is expected to bolster the biopharmaceutical industry, positioning China as a global center for biotherapy [10] Areas of Growth - Four key areas for significant advancements in biomanufacturing are identified: biomedicine and high-end medical devices, agricultural biotechnology, bioplastics, and marine biomanufacturing [11][12]

百奥赛图（北京）医药科技股份有限公司 首次公开发行股票并在科创板上市 | 序号 | 文件名称 | 页码 | | --- | --- | --- | | 1 | 发行保荐书 | 1-41 | | 2 | 财务报表及审计报告 | 42-241 | | 3 | 审阅报告 | 242-325 | | 4 | 内部控制审计报告 | 326-339 | | 5 | 经注册会计师鉴证的非经常性损益明细表 | 340-356 | | 6 | 法律意见书 | 357-1203 | | 7 | 律师工作报告 | 1204-1552 | | 8 | 发行人公司章程（草案） | 1553-1616 | | 9 | 中国证监会同意本次发行注册的文件 | 1617-1618 | 招股意向书附录 中国国际金融股份有限公司 关于百奥赛图（北京）医药科技股份有限公司 首次公开发行股票并在科创板上市的 发行保荐书 保荐机构 （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 2025 年 11 月 1 关于百奥赛图（北京）医药科技股份有限公司 首次公开发行股票并在科创板上市的 发行保荐书 中国证券监督管理委员会、上海证券 ...